Elacestrant Significantly Improves PFS Over SOC in Advanced ER+ Metastatic Breast Cancer
March 5th 2022Elacestrant was found to result in a statistically significant and clinically meaningful improvement in progression-free survival over standard-of-care treatment in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who previously received CDK4/6 inhibitors.
Read More